Polyrizon Ltd. (PLRZ) stock
Close on Nov 13, 2026Market cap $17.77MP/E 2.3Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $17.77M
- P/E ratio
- 2.3
- Price to sales
- –
- Price to book
- 0.73
- Dividend yield
- –
- Free cash flow yield
- -25.52%
Fundamentals
- Net income
- -$3.34M
- EPS, diluted
- $4.90
- Free cash flow
- -$4.54M
Trading
- Previous close
- $11.48
- Open
- $11.00
- Day's range
- $10.74 – $11.19
- Volume
- 5,746
- Average volume (20 days)
- 16,068
- Beta (5 years)
- 2.04
- 52-week range
- $2.88 – $18.20
- RSI (14 days)
- 56.1
- Volatility (1 year)
- 204.0%
- Relative volume
- 0.12×
- WACC
- 15.3%
Market cap history
Month-end market cap since 2024, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | PLRZ | S&P 500 | Difference | PLRZ per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +13.4% | -3.0% | +16.5 pts | ||
| 3 months | +2.8% | -2.8% | +5.6 pts | ||
| Year to date | +30.2% | +11.5% | +18.7 pts | ||
| 1 year | +139.1% | +13.5% | +125.6 pts |
Five years at a glance
Fiscal years 2021 to 2025, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Polyrizon filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Polyrizon
Surgical & Medical Instruments & Apparatus
Polyrizon Ltd. is a development-stage biotechnology company focused on designing and developing biopolymer-based products for medical and therapeutic uses. Its core development efforts center on its Capture and Contain (C&C) product candidates, including the PL-16 candidate, which create a physical barrier to block influenza and allergens from reaching the nasal epithelial tissue. The company also advances other product candidates utilizing its Trap and Target (T&T) platform technology designed for nasal delivery of active pharmaceutical ingredients (APIs). As a clinical-stage biotechnology firm, its technologies are targeted toward patient populations affected by airborne allergens, respiratory viral infections, and related conditions.
Company profile, executives and historyPolyrizon stock: common questions
What is Polyrizon's stock price?
PLRZ closed at $11.05 on Nov 13, 2026, down 3.75% on the day. Over the past 52 weeks it traded between $2.88 and $18.20.
What is Polyrizon's market cap?
Polyrizon was worth $17.77M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is PLRZ's P/E ratio?
PLRZ trades at 2.3 times earnings, based on diluted earnings per share of $4.90 over fiscal 2025.
Does Polyrizon pay a dividend?
No. Polyrizon has not paid a cash dividend over the last twelve months.
How has PLRZ stock performed over the past year?
Including dividends, PLRZ returned +139.1% over the past year, against +13.5% for the S&P 500.
How many PLRZ shares are sold short?
0M shares were sold short at the latest FINRA report, 4.56% of the float, or 4.0 days of average trading volume.
Who are Polyrizon's competitors?
Companies most similar to Polyrizon by business, industry and size include PYPD, DRTS, SGP, QTEX, MBOT.
See a number that looks wrong?